Media mentions

<p>Teresa Tarragó. Image: El Periódico</p>
07 Dec 2018

A public-private consortium designs a new therapy to treat solid tumours

Expansión, El Periódico de Catalunya and Diario de Córdoba, among other media, have published articles about the biotechnologist Iproteos, a company created in 2011 by the scientists Teresa Tarragó and Ernest Giralt and based on the transfer of a technology developed atIRB Barcelona and the University of Barcelona (UB).

<p>Image: SINC</p>
28 Nov 2018

The origin of cancer: a magnifying glass to investigate the Big Bang tumor

SINC AGENCY & OTHER MEDIA

SINC, El Público, Catalunya Vanguardista and the newspaper Heraldo de Aragón, have published an article about the process and conditions that triggers cancer according to a study published in the journal Science that raises new theories about aging.

<p>Image: IRB Barcelona</p>
21 Nov 2018

A study suggests that epigenetic therapies could lead to the appearance of aggressive tumors

LA VANGUARDIA & OTHER MEDIA

La Vanguardia, Cope, Revista Genética, among other media, have each published an article about the latest study led by ICREA researchers Salvador Aznar Benitah and Fran Supek.

Contact

<p>Sonia Armengou</p>
Sònia Armengou
Section Head of Communications
Tel: +34 93 40 37255

Basic information about IRB

Quick facts

IRB Barcelona has been awarded the "HR Excellence in Research" logo. This recognition reflects the commitment of the Institute to continuously improving its human resources policies in line with the European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers. The award confirms the efforts of the Institute to ensure fair and transparent recruitment and appraisal procedures. Click here for more information.

IRB Barcelona is home to nearly 450 research, technical and support staff from 35 countries who share the common goal of contributing to the advancement of the biomedical sciences through investigator–driven research, and improving quality of life by applying advances in this field.

The convergence of biology, chemistry, and structural and computational biology is unique at IRB Barcelona and opens a strategic window to gain insight into basic molecular processes in health and disease.

Research is conducted by 23 groups organized into 5 interdisciplinary programmes. Each programme includes a diverse faculty of researchers with overlapping scientific interests. The research areas have been structured to be highly interactive, fostering multidisciplinarity by combining modern molecular biology, classical genetics, biochemistry, structural biology, bioinformatics, systems biology, advanced microscopy, and genomic and proteomic approaches.

Our Board of Trustees comprises members of the Catalan Government (from the Department of Economy and Competitivity and the Department of Health), the University of Barcelona, a representative from the BBVA Foundation as well as internationally renowned scientists.